Please assess the completion status of the following clinical trial:

Trial Title: CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* mycological diagnosis of candidemia and/or invasive candidiasis from a sample taken less than or equal to 96 hours before randomization (defined as: at least 1 blood culture positive for Candida or positive test for Candida from a sponsor approved rapid diagnostic test or positive gram stain for yeast or positive culture for Candida spp. from a specimen obtained from a normally sterile site)~* willing to initiate or continue medical treatment to cure infections, including receipt of antibiotics and surgical procedures, if required. Patients receiving only medications and measures for comfort and not cure should not be enrolled.~* female subjects of child bearing potential \<2 years post menopausal must agree to one barrier method and one highly effective method of birth control or sexual abstinence.~* male subjects must be vasectomized, abstain from sexual intercourse, or agree to use barrier contraception (condom with spermicide), and also agree not to donate sperm from first dose of CD101 (Day 1) until 90 days following last administration of study drug.~* willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally acceptable representative must provide informed consent on their behalf.~* presence of one or more systemic signs attributable to candidemia and/or invasive candidiasis~Exclusion Criteria:~* Any of the following forms of IC:~  1. Septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed)~ 2. Osteomyelitis~ 3. Endocarditis or myocarditis~ 4. Meningitis, endophthalmitis, or any central nervous system infection~* neutropenia~* alanine aminotransferase or aspartate aminotransferase levels \>10 fold the upper limit of normal~* severe hepatic impairment in subjects with a history of chronic cirrhosis~* greater than 48 hours systemic antifungal treatment at approved doses to treat candidemia~* pregnant females~* lactating females who are nursing~* known hypersensitivity to CD101, caspofungin, any echinocandin, or to any of their excipients~* previous participation in this or any previous CD101 study~* recent use of an investigational medicinal product within 28 days of first dose of study drug or presence of an investigational device at the time of screening~* Principal Investigator considers the subject should not participate~* presence of indwelling vascular catheter or device that cannot be removed and is likely to be the source of candidemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down.
- Group 3 (Type: ACTIVE_COMPARATOR): Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg \[4 capsules\] on the first day followed by 400 mg \[2 capsules\]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind.
- Group 2 (Type: EXPERIMENTAL): Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down.

Based on this trial design, predict the completion outcome and termination type (if applicable).